Time-Dependent Effects of Individual and Combined Treatments With Nebivolol, Lisinopril, and Valsartan on Blood Pressure and Vascular Reactivity to Angiotensin II and Norepinephrine. 2021

Diego Lezama-Martinez, and Maria Elena Hernandez-Campos, and Jazmin Flores-Monroy, and Ignacio Valencia-Hernandez, and Luisa Martinez-Aguilar
Laboratory of Pharmacology, F.E.S.-Cuautitlan, 7180Universidad Nacional Autonoma de Mexico, Cuautitlan Izcalli, Mexico, Mexico.

Clinical guidelines suggest the combination of 2 drugs as a strategy to treat hypertension. However, some antihypertensive combinations have been shown to be ineffective. Therefore, it is necessary to determine whether differences exist between the results of monotherapy and combination therapy by temporal monitoring of the responses to angiotensin II and norepinephrine, which are vasoconstrictors involved in the development of hypertension. Thus, the purpose of this work was to determine the vascular reactivity to angiotensin II and norepinephrine in spontaneously hypertensive rat (SHR) aortic rings after treatment with valsartan, lisinopril, nebivolol, nebivolol-lisinopril, and nebivolol-valsartan for different periods of time. In this study, male SHR and Wistar Kyoto normotensive (WKY) rats were divided into 7 groups treated for 1, 2, and 4 weeks: (1) WKY + vehicle, (2) SHR + vehicle; (3) SHR + nebivolol; (4) SHR + lisinopril; (5) SHR + valsartan; (6) SHR + nebivolol-lisinopril; and (7) SHR + nebivolol-valsartan. Blood pressure was measured by the tail-cuff method, and vascular reactivity was determined from the concentration-response curve to angiotensin II and norepinephrine in aortic rings. The results showed that the combined and individual treatments reduced mean blood pressure at all times evaluated. All treatments decreased vascular reactivity to angiotensin II; however, in the case of lisinopril and nebivolol-lisinopril, the effect observed was significant up to 2 weeks. All treatments decreased the reactivity to norepinephrine up to week 4. These results show a time-dependent difference in vascular reactivity between the pharmacological treatments, with nebivolol-valsartan and nebivolol-lisinopril being both effective combinations. Additionally, the results suggest crosstalk between the renin-angiotensin and sympathetic nervous systems to reduce blood pressure and to improve treatment efficacy.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D011918 Rats, Inbred SHR A strain of Rattus norvegicus with elevated blood pressure used as a model for studying hypertension and stroke. Rats, Spontaneously Hypertensive,Rats, SHR,Inbred SHR Rat,Inbred SHR Rats,Rat, Inbred SHR,Rat, SHR,Rat, Spontaneously Hypertensive,SHR Rat,SHR Rat, Inbred,SHR Rats,SHR Rats, Inbred,Spontaneously Hypertensive Rat,Spontaneously Hypertensive Rats
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D000068577 Nebivolol A cardioselective ADRENERGIC BETA-1 RECEPTOR ANTAGONIST (beta-blocker) that functions as a VASODILATOR through the endothelial L-arginine/ NITRIC OXIDE system. It is used to manage HYPERTENSION and chronic HEART FAILURE in elderly patients. Alpha,Alpha'-(Iminobis(Methylene))bis(6-Fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol,Bystolic,Lobivon,Nebilet,Nebivolol Hydrochloride,R 67555,R-67555,Silostar,67555, R,Hydrochloride, Nebivolol,R67555
D000068756 Valsartan A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION. CGP 48933,Diovan,Kalpress,Miten,N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine,Nisis,Provas,Tareg,Vals,48933, CGP
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Diego Lezama-Martinez, and Maria Elena Hernandez-Campos, and Jazmin Flores-Monroy, and Ignacio Valencia-Hernandez, and Luisa Martinez-Aguilar
September 2012, Journal of clinical hypertension (Greenwich, Conn.),
Diego Lezama-Martinez, and Maria Elena Hernandez-Campos, and Jazmin Flores-Monroy, and Ignacio Valencia-Hernandez, and Luisa Martinez-Aguilar
January 1985, The American journal of physiology,
Diego Lezama-Martinez, and Maria Elena Hernandez-Campos, and Jazmin Flores-Monroy, and Ignacio Valencia-Hernandez, and Luisa Martinez-Aguilar
March 1965, American journal of obstetrics and gynecology,
Diego Lezama-Martinez, and Maria Elena Hernandez-Campos, and Jazmin Flores-Monroy, and Ignacio Valencia-Hernandez, and Luisa Martinez-Aguilar
April 1976, Diabetes,
Diego Lezama-Martinez, and Maria Elena Hernandez-Campos, and Jazmin Flores-Monroy, and Ignacio Valencia-Hernandez, and Luisa Martinez-Aguilar
August 1986, Prostaglandins,
Diego Lezama-Martinez, and Maria Elena Hernandez-Campos, and Jazmin Flores-Monroy, and Ignacio Valencia-Hernandez, and Luisa Martinez-Aguilar
January 1997, Artery,
Diego Lezama-Martinez, and Maria Elena Hernandez-Campos, and Jazmin Flores-Monroy, and Ignacio Valencia-Hernandez, and Luisa Martinez-Aguilar
December 1982, Diabetes,
Diego Lezama-Martinez, and Maria Elena Hernandez-Campos, and Jazmin Flores-Monroy, and Ignacio Valencia-Hernandez, and Luisa Martinez-Aguilar
May 1983, The Tohoku journal of experimental medicine,
Diego Lezama-Martinez, and Maria Elena Hernandez-Campos, and Jazmin Flores-Monroy, and Ignacio Valencia-Hernandez, and Luisa Martinez-Aguilar
September 2003, Hypertension (Dallas, Tex. : 1979),
Diego Lezama-Martinez, and Maria Elena Hernandez-Campos, and Jazmin Flores-Monroy, and Ignacio Valencia-Hernandez, and Luisa Martinez-Aguilar
November 1990, The Tohoku journal of experimental medicine,
Copied contents to your clipboard!